BS-181

Igama Lekhemikhali:

I-N5-(6-aminohexyl)-N7-benzyl-3-isopropylpyrazolo[1,5-a]pyrimidine-5,7-diamine hydrochloride

Ikhodi ye-SMILES:

CC(C1=C2N=C(NCCCCCCN)C=C(NCC3=CC=CC=C3)N2N=C1)C.[H]Cl

Ikhodi ye-InChi:

I-InChI=1S/C22H32N6.ClH/c1-17(2)19-16-26-28-21(25-15-18-10-6-5-7-11-18)14-20(27-22( 19)28 )24-13-9-4-3-8-12-23;/h5-7,10-11,14,16-17,25H,3-4,8-9,12-13,15,23H2, 1-2H3,(H,24,27);1H

I-InChi Key:

NVIJWMOQODWNFN-UHFFFAOYSA-N

Igama elingukhiye:

Ukunyibilika: 

Isitoreji: 

Incazelo:

I-BS-181 iyi-CDK inhibitor ekhetha kakhulu ye-CDK7 ene-IC(50) engu-21 nmol/L. Ukuhlolwa kwamanye ama-CDK kanye namanye ama-kinase angu-69 kubonise ukuthi i-BS-181 ivimbele i-CDK2 kuphela ekugxilweni okungaphansi kuka-1 micromol/L, i-CDK2 ivinjwe ngokuphindwe izikhathi ezingu-35 ngokunamandla (IC(50) 880 nmol/L) kune-CDK7. Kumaseli e-MCF-7, i-BS-181 ivimbele i-phosphorylation yama-CDK7 substrates, yakhuthaza ukuboshwa komjikelezo wamaseli kanye ne-apoptosis ukuvimbela ukukhula kwemigqa yamangqamuzana omdlavuza, futhi yabonisa imiphumela ye-antitumor ku-vivo.

Ithagethi: CDK7